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This panel presented data on host genes that
influence susceptibility to or manifestations of
four infectious diseases: Puumala hantavirus
infection, tuberculosis (TB), Lyme disease, and
AIDS. Gus Birkhead, Council of State and
Territorial Epidemiologists, introduced the ses-
sion, highlighting its timeliness in relation to the
rapidly emerging body of data on our 100,000
human genes that stems from the Human
Genome and related projects.
The presentations introduced several ap-
proaches to identifying a host gene–infectious
disease interaction. Panelists presented case-
control studies of hantavirus infection, AIDS, TB,
and Lyme disease that used the candidate gene
approach; the new approach, genome scanning by
microsatellites to identify genes associated with
TB susceptibility, was also described. Candidate
genes were chosen on the basis of pathology of the
infectious disease (human leukocyte antigen
[HLA], tumor necrosis factor [TNF], the antigen
processing [TAP]), mouse genetic studies of the
pathogen (NRAMP1 in TB), or epidemiologic
findings of disease severity (Vitamin D and TB).
Susceptibility-Associated Major
Histocompatibility Complex (MHC)
Haplotype in Severe Puumala Hantavirus
Infection
Annti Vaheri, Haartman Institute, Univer-
sity of Helsinki, described the epidemiology of
hantavirus infections in Northern Europe. The
pathogens, enveloped RNA viruses primarily of
the Puumala and Dobrava genotypes, are carried
by rodents such as mice and voles and cause a
range of disease in humans. While the epidemics
in the United States are of hantaviruses that
cause primarily pulmonary disease, in northern
Europe, renal disease is the primary pathologic
manifestation, as evidenced by increased capil-
lary permeability, infiltrates of CD8+ T cells,
high levels of ICAM-1, and expression of TNF-a
and transforming growth factor (TGF)-ß. Al-
though most infections with these viruses are
probably subclinical or cause mild disease, in 10%
of patients disease may progress to shock, 5%
may require dialysis, and some may die. Of those
who recover, renal damage may later result in
chronic hypertension. Because hantaviruses are
variable and are usually transmitted as swarms
of viruses, it was proposed that host factors, such
as HLA genes, might influence the spectrum of
disease. Indeed, this has been shown to be the
case. Persons who express the HLA-B8 genes had
more severe disease with lower blood pressures,
higher creatinine (1), and more virus in the urine
and blood by polymerase chain reaction (PCR) (2).
Persons with HLA-B27 had milder disease (3).
The finding of TNF-a expression in the kidney of
infected patients prompted an analysis of the
TNF 1 and 2 alleles (at positions -308 and -238) by
restriction fragment length polymorphism
(RFLP), and as might have been predicted from
their linkage to the HLA-A1-B8-DR3 haplotype,
nearly all who progressed to shock expressed the
TNF 2 allele (M. Kanerva, unpub. data). This
allele has been linked to high TNF production (4).
Because the HLA-A1-B8-DR3 MHC haplo-
type is associated with insulin-dependent
diabetes mellitus and other autoimmune dis-
eases that may have a viral etiology, it was asked
if molecular mimicry could explain the associa-
tion of this haplotype with the renal disease of
Puumala virus infection. Dr. Vaheri stated that
no such evidence exists and that the association
probably reflects a propensity to a particular type
of immune response that results in disease.
Whether the genetic associations observed with
Puumala hantavirus disease are due to a primary
association with the TNF 2 allele or the linked
HLA alleles is not known and deserves future
research. Another important field is the mapping
of HLA-restricted epitopes in hantaviruses.
Host Susceptibility to TB in Africa
Although TB has been present in human
populations for millennia, its reemergence as a
public health problem and the new tools of
molecular genetics have provided an impetus to
study host genetic susceptibility to TB disease.
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Richard Bellamy, Wellcome Trust Center for
Human Genetics, presented studies that used
both candidate- and genome-screening ap-
proaches to define these factors in African
populations. As stated during the question-and-
answer session, many studies of TB should be
considered studies of TB disease rather than TB
susceptibility, since most persons, particularly in
Africa, are TB infected, but (at least in HIV-
negative populations) fewer than 10% become ill.
Dr. Bellamy’s studies were carried out in
populations with low HIV prevalence, HIV-
infected persons were excluded, and disease was
defined as smear-positive TB. Historically, in
most populations, particularly in The Gambia
and South Africa, the sources of patients and
controls for these studies, TB is predominantly a
disease of males. Previous studies of mono- and
dizygotic twins have also suggested a genetic
component (reviewed in 5).
One of the studies described by Dr. Bellamy
used new tools from the human genome and other
projects called microsatellite markers (intronic
sections of cytosine, adenine repeats) and
automated robotic DNA typing using four-color
fluorescent labels with 20 markers per lane of
large gels that are scanned and analyzed by
software such as GeneScan 672 and Genotyper
1.2. He analyzed 92 sibling-pairs from The
Gambia and South Africa. Cosegregation with TB
was identified for markers on chromosomes 3, 5, 6,
8, 9, 15, and the X chromosome. A second study of 83
sibling-pairs from the same countries again linked
the same sites on Xq and 15p with lod scores of >2.
While these studies do not identify the genes in
question, further studies of these regions may
reveal the relevant genes (e.g., the microsatellite
region identified on Xq is close to genes encoding the
CD40 ligand and human LAMP).
Bellamy’s group identified two additional
genes associated with TB in candidate gene
association studies of African TB cases and
ethnically matched controls (6). The human
homologue NRAMP1 of the mouse Bcg gene that
confers resistance to bacillus Calmette-Guérin
has been located on chromosome 2q35. Four
polymorphisms in NRAMP1 were studied with
microsatellite markers and probes that distin-
guished single-base substitutions and a 4-bp
deletion in the gene. While all four polymor-
phisms were associated with TB, two, one
intronic and another in the 3' untranslated
region, were particularly overrepresented in TB
patients; persons heterozygous for INT4 GC and
3'UTR deletion had a fourfold increased risk of
having TB (6). The 3'UTR allele is of unusually
high prevalence in the West African population
studies but is uncommon in Europeans. This may
partly explain the higher susceptibility to TB in
African Americans compared with other ethnic
groups. While the physiologic function of
NRAMP1 has not been defined, it may affect
phagolysosome function. Dr. Bellamy’s data
suggest that the polymorphisms they have
defined or linked polymorphisms may alter
NRAMP1 function and therefore the host’s ability
to clear intracellular pathogens. In vitro studies
to address the effect of these polymorphisms on
macrophage function are in progress.
Dr. Bellamy also presented unpublished data
on vitamin D receptor genotypes and susceptibil-
ity to TB disease. This gene was chosen because of
clinical and laboratory data suggesting vitamin D
may be important in host defenses against TB
(7,8). He observed a low prevalence of the
homozygous t vitamin D receptor genotype  in TB
cases but not in controls. This genotype is also
associated with increased risk for osteoporosis
(9,10). These findings raise the question whether
administering vitamin D to populations at risk
for TB disease might be a simple public health
measure to reduce the disease. However, the
effect of such therapy might be hard to estimate
because of the low prevalence of the tt
homozygous genotype.
The genes (e.g., HLA) identified in these and
other studies are certainly not the only genes
involved in host susceptibility to TB. Dr. Bellamy
estimated that together they account for less
than 2% of the total familial clustering effect in
this disease.
HLA and the Pathogenesis of Lyme
Arthritis
Host responses to another bacterium, the
spirochete Borrelia burgdorferi, and the clinical
spectrum of Lyme arthritis were discussed by
Allen Steere, Department of Rheumatology and
Immunology, New England Medical Center,
Boston, Massachusetts. Another vector-borne
human pathogen, B. burgdorferi causes a
multisystem disease that may affect the skin,
nervous system, heart, or joints. Arthritis is a
major late manifestation of the illness. Although
all manifestations are usually treatable with
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with Lyme arthritis have persistent joint inflam-
mation for months or even years after antibiotic
therapy. In these patients, PCR tests for B. burg-
dorferi DNA in joint fluid have been negative after
antibiotic treatment, which suggests that joint
inflammation may sometimes continue after the
spirochete has been eradicated from the joint.
Dr. Steere’s group is studying host factors
that may be important in the pathogenesis of
chronic, treatment-resistant Lyme arthritis.
Studies of HLA class II alleles have shown that
HLA-DRB1*0401 alleles are associated with
chronic Lyme arthritis and lack of response to
antibiotic therapy (11). This allele is also
associated with an increased risk of developing
severe rheumatoid arthritis (12). In a study of
antibody responses in patients throughout the
course of Lyme disease, immunoglobulin G (IgG)
responses to outer-surface protein A (OspA) and
OspB of the spirochete often developed near the
beginning of prolonged episodes of arthritis (13).
Arthritis lasted considerably longer after treat-
ment in patients with HLA-DR4 and OspA and
OspB antibody reactivity than in those who
lacked responses to these proteins (13). The
cellular arm of the immune response has also
been examined by Dr. Steere’s group, and persons
with treatment-resistant Lyme arthritis usually
have T cells that react with many OspA epitopes,
whereas treatment-responsive patients usually do
not. A possible explanation for these findings is that
the T-cell response to OspA in patients with
treatment-resistant Lyme arthritis may cross-react
with a self antigen in the joint, and the response to
this self antigen may continue to cause joint
inflammation for months or even years after the
eradication of the spirochete from the joint.
How does one treat patients with Lyme
arthritis who do not appear to respond to therapy?
Dr. Steere recommended that if they have not
responded to antibiotics after 2 months and the
PCR test on joint fluid is negative for B. burgdorferi
DNA, patients should be treated with antiinflam-
matory agents. When asked whether HLA genes
might influence Osp-based vaccines for Lyme
disease, Dr. Steere noted that studies to address
this question have not yet been carried out.
Host Genes, HIV Susceptibility, and
Disease Course
The rapidly growing and complex body of
knowledge on the host genes that influence
susceptibility to HIV infection and progression to
AIDS was reviewed by Richard Kaslow,
Department of Epidemiology, University of
Alabama, Birmingham, Alabama. The studies
reported by Kaslow and others in the last 2 years
have greatly benefited from several longitudinal
cohort studies, some focusing on HIV-infected
seroconverters or HIV-exposed persons in the
United States and Europe. More than 10 years
after these cohorts have been established,
adequate power to address the role of candidate
genes in transmitting HIV horizontally and
vertically and in affecting the rate of disease
progression has been obtained, while increased
knowledge of HIV’s mode of cellular entry has
provided new candidate genes to study. HIV
enters cells through an interaction with both CD4
and a chemokine receptor of the 7 Tm family (14).
Dr. Kaslow first reviewed the role of genes in
encoding chemokine receptors (CCR5 and CCR2)
and chemokines (SDF-1) in HIV disease. While
CCR5 has multiple allelic variants in its coding
region (15), the deletion of a 32-bp segment
results in a nonfunctional receptor (reviewed in
16), thus preventing HIV entry; two copies of this
gene provide strong protection against HIV
infection in epidemiologic studies, although the
protection is not absolute. This gene is found in
up to 20% of Europeans but is rare in Africans and
Asians. Multiple studies of HIV-infected persons
have shown that presence of one copy of this gene
delays progression to AIDS by about 2 years. A
mutation in another chemokine receptor gene,
that coding for CCR2, has also been reported by
several groups to be associated with a delayed
progression to AIDS (reviewed in 17). This
polymorphism (a position 64 Val®Ile substitution)
does not appear likely to affect receptor function,
and the mutation may be linked to another
polymorphism in the promotor of CCR5 (18).
Nevertheless, studies of persons with both CCR2
64I polymorphism and CCR5 delta 32 deletion
suggest the effect of both genes on HIV disease
progression is additive (19). A polymorphism in the
chemokine SDF-1, which binds to another HIV
entry receptor, CXCR4, also delays HIV progres-
sion and similarly appears additive to the effects of
the CCR2 and CCR5 polymorphisms (20).
Dr. Kaslow also reviewed studies of the HLA
system (at the Class I HLA A, B, C and Class II DR
and DQ and the antigen processing [TAP] loci) and
how complex combinations of different HLA alleles
alter the risk of developing AIDS in several cohorts
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combinations of HLA alleles appear to delay HIV
progression by a variable number of years and to be
additive to the effects of the chemokine gene
polymorphisms described above.
These new findings about HIV and host genes
have led to new approaches to AIDS treatments,
such as those directed at chemokine receptors,
and hold great promise for advancing our ability
to combat this disease.
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